Concord Medical Services (CCM) has released an update.
Concord Medical Services Holdings Limited, a major provider of cancer care in China, has announced that its subsidiary Guangzhou Concord Cancer Center has obtained a license to procure large medical equipment, specifically for its proton therapy equipment. This marks a significant step following the installation of proton equipment in 2020 and the commencement of clinical trials in 2022, with the center planning to launch proton therapy treatment services soon. The news also follows Concord Healthcare, another subsidiary, being listed on the Hong Kong Stock Exchange earlier in the year.
For further insights into CCM stock, check out TipRanks’ Stock Analysis page.
